^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Pembroria (pembrolizumab biosimilar)

    i
    Associations
    News

    Trials

    Company:
    Biocad
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations (SWOG S2001) (NCT04548752)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/22/2021
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    BRCA1 • BRCA
    |
    BRCA mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin • Pembroria (pembrolizumab biosimilar)
    Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NCT02194738)
    Phase N/A
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/26/2014
    Primary completion :
    09/28/2026
    Completion :
    09/28/2026
    EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4
    |
    EGFR mutation • ALK rearrangement
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)
    Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial (ACCIO) (NCT04267848)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/16/2020
    Primary completion :
    12/15/2025
    Completion :
    12/15/2025
    EGFR • PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • Pembroria (pembrolizumab biosimilar) • liposomal gemcitabine (FF-10832)
    Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery (SWOG 1512) (NCT02775851)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/06/2017
    Primary completion :
    04/14/2023
    Completion :
    05/15/2026
    TMB • CD8 • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative (NCT04929041)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/07/2022
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    EGFR • PD-L1 • ALK • ROS1
    |
    PD-L1 expression • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)
    Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma (ETCTN 10183) (NCT03854474)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    11/18/2019
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    PD-L1 • PD-1
    |
    EZH2 mutation
    |
    Keytruda (pembrolizumab) • cisplatin • Tazverik (tazemetostat) • Pembroria (pembrolizumab biosimilar)
    Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (NCI-2021-13902) (NCT05172258)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    07/26/2022
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    PD-L1
    |
    Keytruda (pembrolizumab) • ipatasertib (RG7440) • Pembroria (pembrolizumab biosimilar)
    Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer (NRG GY020) (NCT04214067)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    04/09/2020
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer (AMBASSADOR) (NCT03244384)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/03/2017
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • Pembroria (pembrolizumab biosimilar)
    Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer (EA5163) (NCT03793179)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    04/05/2019
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    EGFR • PD-L1 • BRAF • ALK • ROS1
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)
    A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma (NCT04708418)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/15/2021
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    BRAF
    |
    Keytruda (pembrolizumab) • vidutolimod (CMP-001) • Pembroria (pembrolizumab biosimilar)
    Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer (NCT05422794)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    05/18/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    HER-2 • PD-L1 • ER • PGR
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • ZEN-3694 • Pembroria (pembrolizumab biosimilar)
    Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer (NCT02954874)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/18/2017
    Primary completion :
    05/31/2026
    Completion :
    05/31/2026
    HER-2 • PD-L1 • ER • PGR • CD4
    |
    PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma (NCT02359565)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    06/03/2015
    Primary completion :
    12/21/2025
    Completion :
    12/21/2025
    PD-L1 • TMB
    |
    TMB-H
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer (NCI-2022-03215) (NCT05353439)
    Phase 1
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    01/28/2025
    Initiation :
    07/27/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    CD4
    |
    Keytruda (pembrolizumab) • Tazverik (tazemetostat) • topotecan • Pembroria (pembrolizumab biosimilar)
    Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer (NCT04576091)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    07/06/2022
    Primary completion :
    11/27/2024
    Completion :
    11/27/2024
    TMB • CD8 • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • elimusertib (BAY 1895344) • Pembroria (pembrolizumab biosimilar)
    Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors (NCT03030378)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    05/30/2018
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    CD4
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer (NCT05673200)
    Phase 1
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    06/05/2024
    Initiation :
    09/25/2023
    Primary completion :
    02/23/2027
    Completion :
    02/23/2027
    HER-2 • PD-L1 • ER • PGR
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • paclitaxel • Inqovi (decitabine/cedazuridine) • Pembroria (pembrolizumab biosimilar)
    Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (SWOG S1404) (NCT02506153)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/22/2024
    Initiation :
    11/10/2015
    Primary completion :
    09/15/2023
    Completion :
    01/23/2025
    CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • Intron A (interferon α-2b) • Pembroria (pembrolizumab biosimilar)
    SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer (NCT05570825)
    Phase 2
    University of Washington
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    04/06/2023
    Primary completion :
    07/01/2027
    Completion :
    07/01/2028
    PD-L1 • ALK • RET • ROS1
    |
    PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement
    |
    Keytruda (pembrolizumab) • SX-682 • Pembroria (pembrolizumab biosimilar)
    Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma (NCT03126630)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    01/10/2024
    Initiation :
    10/04/2018
    Primary completion :
    07/08/2023
    Completion :
    09/21/2024
    PD-L1 • MSLN
    |
    PD-L1 expression • MSLN expression
    |
    Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343) • Pembroria (pembrolizumab biosimilar)
    Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    11/03/2023
    Initiation :
    04/04/2016
    Primary completion :
    10/04/2023
    Completion :
    10/11/2024
    PD-L1 • BRAF • ALK • ROS1 • CD4
    |
    BRAF V600 • ALK mutation • ROS1 mutation
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma (NCT03063632)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/25/2023
    Initiation :
    12/14/2017
    Primary completion :
    04/08/2021
    Completion :
    03/14/2023
    IFNG • CTAG1B
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b) • Pembroria (pembrolizumab biosimilar)
    Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma (NCT05986331)
    Phase 3
    Biocad
    Active, not recruiting
    Last update posted :
    09/21/2023
    Initiation :
    07/18/2022
    Primary completion :
    12/31/2023
    Completion :
    12/31/2024
    PROCR
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies (NCT05739006)
    Phase 1
    Biocad
    Active, not recruiting
    Last update posted :
    08/02/2023
    Initiation :
    02/08/2021
    Primary completion :
    06/21/2022
    Completion :
    08/31/2023
    PD-L1 • PROCR
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)